Additionally, complete inhibition of the PI3K and MAPK signaling pathways is required for tumor control.224 The results of a clinical trial on treatment with both PI3K and MAPK signaling inhibitors support this hypothesis, as PI3K and MAPK therapies used in combination improved the treatment efficacy compared to that achieved with either inhibitor alone. The gene discussed is PIK3CG; the disease is neoplasm.